Case Studies

Gaining payer insights to transform the value message of an orphan drug across Europe

26/04/2023

Author:

Sarah Bailey
About the Author

Article Tags

HTA HTA Process Orphan Drugs

Share this article

Related articles

Insider Insights
20.05.2026
Orphan medicines in the EU: Key EU General Pharma ...

EU GPL: A Shift Towards More Selective Incentives for Orphan Drug Manufacturers In March 2026, the ...

Read more
Articles
06.05.2026
Playing the Long Game: How Early Scientific Advice...

Early HTA scientific advice reduces price and reimbursement risk by informing ev...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch